

# Första intrycket Elicera Therapeutics kv1 2026: Företrädesemission om 73 MSEK

Carlsquare Equity Research har publicerat en första kommentar på rapporten för det första kvartalet.

[Läs kommentaren här.](#)

## Om Carlsquare

Carlsquare is a global research firm and financial advisor focusing on M&A, Equity Research and Growth Equity. Carlsquare has 170 employees with deep sector knowledge in all 11 GICS sectors. The senior equity research team has extensive experience in the stock environment and several business sectors. The team produces company research reports, independent valuations and trading notes. The group have offices in Canada, Denmark, France, Germany, Poland, Sweden, United Kingdom and United States. [Read more](#)

[www.carlsquare.com](http://www.carlsquare.com)

## Kontakter

### MARKUS AUGUSTSSON

Head of Equity Research

[markus.augustsson@carlsquare.com](mailto:markus.augustsson@carlsquare.com)

+46 (0)76 235 03 20

### NIKLAS ELMHAMMER

Senior Equity Analyst

[niklas.elmhammer@carlsquare.com](mailto:niklas.elmhammer@carlsquare.com)

+46 (0)70 898 39 59

## Bifogade filer

[Första intrycket Elicera Therapeutics kv1 2026: Företrädesemission om 73 MSEK](#)